Associate Director
Takeda
Cambridge, Massachusetts
Dr. Sugimoto is Associate Director in Global DMPK at Takeda Boston to lead the research project support activity for the rare disease gene therapy. His team currently focuses on nonclinical gene therapy assay support, including immunocapture-LC/MS-based biomarker and transgene protein assay, LBA-based transgene protein assay, enzymatic activity and droplet digital PCR-based genomic assay platform. He served as a chair of the Bioanalysis Center of Excellence in Global DMPK at Takeda to lead the discussion to support the company’s pipeline. Previously, he served as a DMPK representative at the drug discovery stage in oncology and neuroscience in Japan.
Dr. Sugimoto received Ph.D. in pharmaceutical science in 2016. He has been a member of the Applied Pharmaceutical Analysis organizing committee and the AAPS Gene and Cell Therapy BA leadership team. He has contributed to multiple scientific journals including Analytical Chemistry, The AAPS Journal, Drug Metabolism and Disposition and patent submission.
Disclosure information not submitted.
Wednesday, October 19, 2022
8:30 AM – 9:00 AM ET